Loading stock data…
MoonLake Immunotherapeutics (MLTX)
$19.91+0.01 (+0.05%)
Market ClosedLast close Jun 29
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MoonLake Immunotherapeutics in the Healthcare sector is trading at $19.91 with a market capitalization of $1.4B. Wall Street consensus targets $27.62 (13 analysts), implying a +38.7% move over the next 12 months. The stock is currently 68% below its 52-week high of $62.75, remaining 12.6% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +38.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$70.02M↓ | -$65.22M↑ | -$71.43M↓ | -$60.70M↓ | -$47.48M |
| Net Income | -$69.71M↓ | -$62.43M↑ | -$69.73M↓ | -$55.22M↓ | -$39.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-101.20%
Volume
Today's trading volume
1.29M
Recent News
How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering
MoonLake Immunotherapeutics recently reported past Week 52 Phase 3 VELA data showing strong efficacy and a consistent safety profile for sonelokimab in moderate-to-severe hidradenitis suppurativa, including adults and adolescents, and followed this with an upsized US$200,000,000 follow-on offering of Class A shares and pre-funded warrants priced around US$20 each. An interesting angle for investors is how MoonLake is pairing positive long-term clinical outcomes with fresh capital...
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
The biotech is floating a relatively sizable secondary share issue.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Easing US-Iran Tensions
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively tra
MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development
The biotech firm upsized its offering to $200 million, up from the previously announced $150 million.
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”